FAS APOPTOTIC GENE POLYMORPHISM (-670A/G) IS ASSOCIATED WITH CLINICAL PHENOTYPES OF SYSTEMIC SCLEROSIS IN A RUSSIAN POPULATION: A PILOT STUDY

The FAS antigen (Apo-1/CD95) is a key molecule of apoptosis in most cell types, including activated immune cells and fibroblasts. The FAS gene promoter region contains a single-nucleotide polymorphism (-670A/G) associated with a substitution of the nucleotide arginine for guanine, which is associated with the predisposition to systemic lupus erythematosus, multiple sclerosis, sarcoidosis, and autoimmune hepatitis.

Objective: to test the hypothesis that the FAS -670А/G polymorphism may predispose to systemic sclerosis (SS), its clinical and autoimmune phenotypes in a Russian patient sample.

Subjects and methods. The instigation enrolled 90 SS patients who were classified according to clinical and autoimmune phenotypes. A control group consisted of 152 apparently healthy unrelated individuals matched for sex and age. The FAS -670А/G polymorphism was studied by polymerase chain reaction, followed by restriction fragment length polymorphism analysis.

Results and discussion. A relatively small sample of Russian patients showed no statistically significant association of the studied FAS -670 A/G polymorphism with the predisposition to SS as a whole and the majority of its clinical and immunological phenotypes. There was a statistically significant positive association of the G allele (the FAS -670 GG+GA genotype) with the presence of digital ulcers and the chronic course of the disease. The G allele (the FAS -670 GG+ GA) was detected less frequently in patients with interstitial lung disease (ILD) than in those without ILD.

Conclusion. The findings show that the FAS -670A>G polymorphism plays a role in the predisposition to some clinical phenotypes of SS in Russian patients.

1. Liakouli V, Manetti M, Pacini A, et al. The-670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. Ann Rheum Dis. 2009;68(4):584-90. doi: 10.1136/ard.2008.088989

2. Broen J, Gourh P, Rueda B, et al. The FAS - 670A>G polymorphism influences susceptibility to systemic sclerosis phenotypes. Arthritis Rheum. 2009;60(12):3815-20. doi: 10.1002/art.24964

3. Cipriani P, Fulminis A, Pingiotti E, et al. Resistance to apoptosis in circulating α/β and γ/δ T lymphocytes from patients with systemic sclerosis. J Rheumatol. 2006;33:2003-14.

4. Wetzig T, Petri JB, Mittag M, Haustein UF. Serum levels of soluble FAS/APO-1 receptor are increased in systemic sclerosis. Arch Dermatol Res. 1998;2904:187-90. doi: 10.1007/s004030050288

5. Kamenitsu S, Ihara K, Saifddin A, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol. 2002;29(6):1183-8.

6. Wasfi YS, Silveria LJ, Jonth A, et al. Fas promoter polymorphisms: genetic predisposition to sarcoidosis in African-Americans. Tissue Antigens. 2008;72(1):39-48. doi: 10.1111/j.1399- 0039.2008.01060.x

7. Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrosis. Tissue Antigens. 2007.Mar;69(3):227-35. doi: 10.1111/j.1399-0039.2006.00794.x

8. Van Veen T, Kalkers NF, Crusius JB, et al. The FAS-670 polymorphism influences susceptibility to multiple sclerosis. J Neuroimmunol. 2002 Jul;128(1-2):95-100. doi: 10.1016/S0165-5728(02)00163-7

9. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581-90. doi: 10.1002/art.1780230510

10. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;Feb 11;16(3):1215. doi: 10.1093/nar/16.3.1215

11. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997 Jun;34(8- 9):577-82. doi: 10.1016/S0161-5890(97)00081-3

12. Meier FM, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EUSTAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2012 Aug;71(8):1355-60. doi: 10.1136/annrheumdis-2011-200742

13. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine (Baltimore). 2002;81:139-53. doi: 10.1097/00005792-200203000-00004

14. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore). 2002;81:154-67. doi: 10.1097/00005792-200203000-00005

15. Mahfoudh W, Bel H Jr, Romdhane A, Chouchane L. A polymorphism in FAS gene promoter correlated with circulating soluble FAS levels. Int J Immunogenet. 2007 Jun;34(3):209-12. doi: 10.1111/j.1744-313X.2007.00676.x